OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 0.5 %

OpGen stock opened at $1.98 on Monday. The stock has a 50 day moving average of $2.20 and a two-hundred day moving average of $3.52. OpGen has a twelve month low of $1.75 and a twelve month high of $38.40.

OpGen (NASDAQ:OPGN) last issued its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 1,140.36%.

Institutional Trading of OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp purchased a new position in OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is currently owned by institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.